{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:24:59Z","timestamp":1791591899374,"version":"4.3.4"},"reference-count":48,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:00:00Z","timestamp":1720828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Cholangiocellular carcinoma (CCA) is the second most common primary liver cancer, with increasing incidence worldwide and inadequate therapeutic options. Intra- and extrahepatic bile ducts have distinctly different embryonic origins and developmental behavior, and accordingly, intra- and extrahepatic CCAs (ICC vs. ECC) are molecularly different. A promising strategy in oncotherapy is targeted therapy, targeting proteins that regulate cell survival and proliferation, such as the MAPK\/ERK and PI3K\/AKT\/mTOR signaling pathways. Inhibitors of these pathways have been tested previously in CCA cell lines. However, these cell lines could not be clearly assigned to ICC or ECC, and the results indicated apoptosis induction by targeted therapeutics. We tested targeted therapeutics (selumetinib, MK2206) in three defined ICC cell lines (HuH28, RBE, SSP25). We observed additive effects of the dual inhibition of the two pathways, in accordance with the inhibition of phospho-AKT and phospho-ERK1\/2 expression. Proliferation was blocked more effectively with dual inhibition than with each single inhibition, but cell numbers did not drop below baseline. Accordingly, we observed G1 phase arrest but not apoptosis or cell death (measured by cleaved caspase-3, AIFM1 regulation, sub-G0\/G1 phase). We conclude that the dual inhibition of the MAPK\/ERK and PI3K\/AKT\/mTOR pathways is highly effective to block the proliferation of ICC cell lines in vitro; however, potential clinical applications must be critically examined, as a proliferation block could also induce resistance to standard therapies.<\/jats:p>","DOI":"10.3390\/cimb46070439","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T16:55:36Z","timestamp":1721321736000},"page":"7395-7410","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Dual Inhibition of PI3 Kinase and MAP Kinase Signaling Pathways in Intrahepatic Cholangiocellular Carcinoma Cell Lines Leads to Proliferation Arrest but Not Apoptosis"],"prefix":"10.3390","volume":"46","author":[{"given":"Jessica","family":"Sch\u00fcler","sequence":"first","affiliation":[{"name":"Institute of Anatomy and Embryology, University Medical Center Goettingen, GAU, 37075 Goettingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Vockerodt","sequence":"additional","affiliation":[{"name":"Institute of Anatomy and Embryology, University Medical Center Goettingen, GAU, 37075 Goettingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloofar","family":"Salehzadeh","sequence":"additional","affiliation":[{"name":"Institute of Anatomy and Embryology, University Medical Center Goettingen, GAU, 37075 Goettingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Becker","sequence":"additional","affiliation":[{"name":"Institute of Anatomy and Embryology, University Medical Center Goettingen, GAU, 37075 Goettingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8337-2296","authenticated-orcid":false,"given":"J\u00f6rg","family":"Wilting","sequence":"additional","affiliation":[{"name":"Institute of Anatomy and Embryology, University Medical Center Goettingen, GAU, 37075 Goettingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.20517\/2394-5079.2021.130","article-title":"Epidemiology of cholangiocarcinoma","volume":"8","author":"Turati","year":"2022","journal-title":"Hepatoma Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.suc.2010.04.011","article-title":"Intrahepatic cholangiocarcinoma","volume":"90","author":"Poultsides","year":"2010","journal-title":"Surg. Clin. N. Am."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: The next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_4","first-page":"748","article-title":"The diagnosis and treatment of cholangiocarcinoma","volume":"111","author":"Vogel","year":"2014","journal-title":"Dtsch. Arzteblatt Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1038\/onc.2012.617","article-title":"Intrahepatic cholangiocarcinoma: Pathogenesis and rationale for molecular therapies","volume":"32","author":"Sia","year":"2013","journal-title":"Oncogene"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1053\/j.gastro.2013.10.013","article-title":"Pathogenesis, diagnosis, and management of cholangiocarcinoma","volume":"145","author":"Rizvi","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.21037\/hbsn.2017.01.02","article-title":"Epidemiology and risk factors: Intrahepatic cholangiocarcinoma","volume":"6","author":"Gupta","year":"2017","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3748\/wjg.14.666","article-title":"Opisthorchis viverrini: The carcinogenic human liver fluke","volume":"14","author":"Kaewpitoon","year":"2008","journal-title":"World J. Gastroenterol. WJG"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000454763","article-title":"Cholangiocellular Carcinoma","volume":"95","author":"Vogel","year":"2017","journal-title":"Digestion"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","article-title":"Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma","volume":"60","author":"Bridgewater","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/jcmm.16151","article-title":"Therapy for advanced cholangiocarcinoma: Current knowledge and future potential","volume":"25","author":"Wang","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Lee, S., Rauch, J., and Kolch, W. (2020). Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21031102"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.3748\/wjg.v13.i48.6470","article-title":"AKT and ERK1\/2 signaling in intrahepatic cholangiocarcinoma","volume":"13","author":"Schmitz","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s10637-014-0149-7","article-title":"Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors","volume":"32","author":"Ewald","year":"2014","journal-title":"Investig. New Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/jnci\/djad046","article-title":"Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma","volume":"115","author":"Spencer","year":"2023","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.jhep.2011.09.022","article-title":"Development of the bile ducts: Essentials for the clinical hepatologist","volume":"56","author":"Strazzabosco","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"151235","DOI":"10.1016\/j.sempedsurg.2022.151235","article-title":"Biliary atresia & choledochal malformation\u2014Embryological and anatomical considerations","volume":"31","author":"Muntean","year":"2022","journal-title":"Semin. Pediatr. Surg."},{"key":"ref_19","unstructured":"(2023, June 29). EMA Pemazyre. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/pemazyre."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-020-00949-4","article-title":"The MAPK and AMPK signalings: Interplay and implication in targeted cancer therapy","volume":"13","author":"Yuan","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/01.sla.0000220040.66012.a9","article-title":"Targeted Molecular Therapy of the PI3K Pathway: Therapeutic Significance of PI3K Subunit Targeting in Colorectal Carcinoma","volume":"243","author":"Rychahou","year":"2006","journal-title":"Ann. Surg."},{"key":"ref_22","first-page":"92","article-title":"Establishment and characterization of a human cholangiocellular carcinoma cell line","volume":"1","author":"Kusaka","year":"1988","journal-title":"Hum. Cell"},{"key":"ref_23","first-page":"245","article-title":"Loss of liver-intestine cadherin in human intrahepatic cholangiocarcinoma promotes angiogenesis by up-regulating metal-responsive transcription factor-1 and placental growth factor","volume":"36","author":"Takamura","year":"2010","journal-title":"Int. J. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.7150\/ijbs.79126","article-title":"Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation","volume":"19","author":"Pan","year":"2023","journal-title":"Int. J. Biol. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s43018-023-00523-0","article-title":"SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancers","volume":"4","author":"Shi","year":"2023","journal-title":"Nat. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"eadj7685","DOI":"10.1126\/scitranslmed.adj7685","article-title":"SRC inhibition enables formation of a growth suppressive MAGI1-PP2A complex in isocitrate dehydrogenase-mutant cholangiocarcinoma","volume":"16","author":"Luk","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1158\/0008-5472.CAN-05-3049","article-title":"Keratoepithelin suppresses the progression of experimental human neuroblastomas","volume":"66","author":"Becker","year":"2006","journal-title":"Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Malik, I.A., Rajput, M., Werner, R., Fey, D., Salehzadeh, N., von Arnim, C.A.F., and Wilting, J. (2022). Differential in vitro effects of targeted therapeutics in primary human liver cancer: Importance for combined liver cancer. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-10247-6"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1038\/sj.onc.1204436","article-title":"Staurosporine induces apoptosis through both caspase-dependent and caspase-independent mechanisms","volume":"20","author":"Belmokhtar","year":"2001","journal-title":"Oncogene"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"19268","DOI":"10.1038\/s41598-021-98948-z","article-title":"Tanshinone IIA affects the malignant growth of Cholangiocarcinoma cells by inhibiting the PI3K-Akt-mTOR pathway","volume":"11","author":"Liu","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_32","first-page":"4032","article-title":"Downregulation of microRNA-425-5p suppresses cervical cancer tumorigenesis by targeting AIFM1","volume":"17","author":"Zhang","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_33","first-page":"3823","article-title":"Dietary flavone is a potent apoptosis inducer in human colon carcinoma cells","volume":"60","author":"Wenzel","year":"2000","journal-title":"Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"10156","DOI":"10.1002\/cam4.5719","article-title":"Comprehensive transcriptomic analysis to identify biological and clinical differences in cholangiocarcinoma","volume":"12","author":"Silvestri","year":"2023","journal-title":"Cancer Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","article-title":"The Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation","volume":"36","author":"Mendoza","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00280-013-2121-1","article-title":"PI3K and MEK inhibitor combinations: Examining the evidence in selected tumor types","volume":"71","author":"Britten","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB Signaling: Navigating the Network","volume":"169","author":"Manning","year":"2017","journal-title":"Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.canlet.2019.05.025","article-title":"AKT and ERK dual inhibitors: The way forward?","volume":"459","author":"Cao","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12935-015-0161-9","article-title":"Inhibition of the AKT pathway in cholangiocarcinoma by MK2206 reduces cellular viability via induction of apoptosis","volume":"15","author":"Wilson","year":"2015","journal-title":"Cancer Cell Int."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/376037a0","article-title":"Identification and inhibition of the ICE\/CED-3 protease necessary for mammalian apoptosis","volume":"376","author":"Nicholson","year":"1995","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1002\/bab.2233","article-title":"Caspase-3: Structure, function, and biotechnological aspects","volume":"69","author":"Asadi","year":"2022","journal-title":"Biotechnol. Appl. Biochem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"7320","DOI":"10.1074\/jbc.M008363200","article-title":"Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis","volume":"276","author":"Slee","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tcb.2020.11.001","article-title":"CDK1, the Other \u201cMaster Regulator\u201d of Autophagy","volume":"31","author":"Odle","year":"2021","journal-title":"Trends Cell Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"104","DOI":"10.7150\/thno.30308","article-title":"Selective Autophagy Regulates Cell Cycle in Cancer Therapy","volume":"9","author":"Zheng","year":"2019","journal-title":"Theranostics"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1200\/jco.2011.29.15_suppl.3004","article-title":"A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors","volume":"29","author":"Tolcher","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1007\/s10637-015-0212-z","article-title":"Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer","volume":"33","author":"Do","year":"2015","journal-title":"Investig. New Drugs"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.semcancer.2017.04.015","article-title":"PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux","volume":"48","author":"Massi","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e1655","DOI":"10.1002\/ctm2.1655","article-title":"PI3K\/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6high uterine leiomyosarcoma to PD-1 blockade","volume":"14","author":"Annibali","year":"2024","journal-title":"Clin. Transl. Med."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/46\/7\/439\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:16:21Z","timestamp":1760109381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/46\/7\/439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,13]]},"references-count":48,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["cimb46070439"],"URL":"https:\/\/doi.org\/10.3390\/cimb46070439","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,13]]}}}